Sequence Information

    • DRAMP ID

    • DRAMP18060

    • Name

    • p2TA(AB103, Reltecimod)

    • Sequence

    • ASPMLVAYDA

    • Description

    • Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).

    • Activity

    • Antibacterial

    • Target Organism

      • No MICs found on DRAMP database

    • Reference

      • Resolution of organ dysfunction as a predictor of long-term survival in necrotizing soft tissue infections: Analysis of the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections trial and a retrospective claims database-linked chart study.(PMID: 33797490)

Clinical Information

    • Medical use

    • Necrotizing soft tissue infections

    • Company

    • Atox Bio Ltd.

    • Stage of Development

    • Phase III

    • Comments

    • No more comments

    • Clinical Trials

    • NCT01417780
    • NCT01417780
    • NCT02469857